Dr. Fernández-Fernández and Dr. Sesma reply

摘要

We thank Dr. Park and colleagues for their interest in our letter. They note another mechanism by which N-acetylcysteine might be useful as adju-vant therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The studies that they cite, along with those that we mentioned, could be the basis to evaluate the hypothetical potential of high-dose acetylcysteine as an anti-vasculitic drug in randomized, placebo-controlled trials in humans.